1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
The objective of this book is to provide health workers with easily accessible information on important aspects of the medicines commonly used at primary care level in Zimbabwe. Medicines are a crucial part of the management of most of our patients, yet many medicines are potentially dangerous if no...t used correctly (by either prescriber or patient). It is important to have up-to-date information not only on the indications for, and the dose of a particular medicine, but also the contra-indications and reasons for special care, possible side effects and interactions with other medicine or medicines. The patient must also have information on how to use the preparation, what side effects may occur, and when to return for help.
more
Information note.
This information note provides a strategic overview of key implementation considerations for diagnostic integration using these devices, and is primarily intended for use by national laboratory services and TB, HIV, and hepatitis programme managers.
It may also be of inte...rest to managers of maternal, newborn and child health programmes and sexual and reproductive health programmes, international and bilateral agencies, and organizations that provide financial and technical support to the relevant national health programmes.
more
PLOS ONE | DOI:10.1371/journal.pone.0133869 July 28, 2015, p.1-16
Information note
Accessed November 2017.
This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implement...ing TB care and prevention and R&D into new tools. This Global Plan has already informed the Global Fund Investment Case and the 2022 G20 deliberations on TB. It will serve as a key document for inspiring and aligning global advocacy efforts, such as for the upcoming UNHLM on TB in 2023.
more
Networking for Policy Change: TB/HIV Participant’s Guide
WHO/HTM/TB/2007.384b
“TB is too often a death sentence for people with AIDS. It does not have to be this
way.”
-Nelson Mandela, International conference on HIV and AIDS, Bangkok, Thailand, July 2004.
WHO/HTM/TB/2007.384a
“TB is too often a death sentence for people with AIDS.
It does not have to be this way.”
-Nelson Mandela, International conference on HIV /AIDS, Bangkok, Thailand, July 2004
Engage - TB
WHO/HTM/TB/2015.27
Collection of country-level good practices
First Edition, July 2009
Trainers’ Manual
Key Populations Brief
Accessed November 2017